Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps

Journal of Allergy and Clinical Immunology

Volumn 118, Issue 5, 2006, Pages 1133-1141

  Gevaert, Philippe ^a   Lang Loidolt, Doris ^c   Lackner, Andreas ^c   Stammberger, Heinz ^c   Staudinger, Heribert ^d   Van Zele, Thibaut ^a   Holtappels, Gabriele ^a   Tavernier, Jan ^b   van Cauwenberge, Paul ^a   Bachert, Claus ^a  

^a Upper airways Research   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

anti IL 5; Chronic rhinosinusitis; eosinophils; IL 5; IL 5 receptor ; nasal polyps

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; EOTAXIN; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; PLACEBO; RESLIZUMAB; SCH 55700; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPY; EOSINOPHIL COUNT; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MULTICENTER STUDY; NOSE POLYP; NOSE SECRETION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-5; MALE; MIDDLE AGED; NASAL MUCOSA; NASAL POLYPS;

EID: 33750508779     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2006.05.031     Document Type: Article

References (26)

1. Bachert C., Gevaert P., Holtappels G., Cuvelier C., and van Cauwenberge P. Nasal polyposis: from cytokines to growth. Am J Rhinol 14 (2000) 279-290
2. Settipane G.A., and Chafee F.H. Nasal polyps in asthma and rhinitis. A review of 6,037 patients. J Allergy Clin Immunol 59 (1977) 17-21
3. Denburg J.A., Sehmi R., and Upham J. Regulation of IL-5 receptor on eosinophil progenitors in allergic inflammation: role of retinoic acid. Int Arch Allergy Immunol 124 (2001) 246-248
4. Sanderson C.J. Interleukin-5, eosinophils, and disease. Blood 79 (1992) 3101-3109
5. Bachert C., Wagenmann M., Hauser U., and Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 99 (1997) 837-842
6. Gevaert P., Bachert C., Holtappels G., Novo C.P., Van der Heyden J., Fransen L., et al. Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy 58 (2003) 371-379
7. Simon H.U., Yousefi S., Schranz C., Schapowal A., Bachert C., and Blaser K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 158 (1997) 3902-3908
8. Greenfeder S., Umland S.P., Cuss F.M., Chapman R.W., and Egan R.W. Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res 2 (2001) 71-79
9. Flood-Page P., Menzies-Gow A., Phipps S., Ying S., Wangoo A., Ludwig M.S., et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112 (2003) 1029-1036
10. Flood-Page P.T., Menzies-Gow A.N., Kay A.B., and Robinson D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167 (2003) 199-204
11. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 (2000) 2144-2148
12. Kips J.C., O'Connor B.J., Langley S.J., Woodcock A., Kerstjens H.A., Postma D.S., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167 (2003) 1655-1659
13. Klion A.D., Law M.A., Noel P., Haverty T.P., and Nutman T.B. Safety and efficacy of the monoclonal anti-interleukin 5 antibody, SCH55700, in the treatment of patients with the hypereosinophilic syndrome. Blood 103 (2004) 2939-2941
14. Plotz S.G., Simon H.U., Darsow U., Simon D., Vassina E., Yousefi S., et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349 (2003) 2334-2339
15. Liu L.Y., Sedgwick J.B., Bates M.E., Vrtis R.F., Gern J.E., Kita H., et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol 169 (2002) 6459-6466
16. Liu L.Y., Sedgwick J.B., Bates M.E., Vrtis R.F., Gern J.E., Kita H., et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 Receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. J Immunol 169 (2002) 6452-6458
17. Foster P.S., Hogan S.P., Yang M., Mattes J., Young I.G., Matthaei K.I., et al. Interleukin-5 and eosinophils as therapeutic targets for asthma. Trends Mol Med 8 (2002) 162-167
18. Foster P.S., Hogan S.P., Ramsay A.J., Matthaei K.I., and Young I.G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 183 (1996) 195-201
19. Mould A.W., Ramsay A.J., Matthaei K.I., Young I.G., Rothenberg M.E., and Foster P.S. The effect of IL-5 and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyperreactivity. J Immunol 164 (2000) 2142-2150
20. Tournoy K.G., Kips J.C., Schou C., and Pauwels R.A. Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness. Clin Exp Allergy 30 (2000) 79-85
21. Tournoy K.G., Kips J.C., and Pauwels R.A. The allergen-induced airway hyperresponsiveness in a human-mouse chimera model of asthma is T cell and IL-4 and IL-5 dependent. J Immunol 166 (2001) 6982-6991
22. Gregory B., Kirchem A., Phipps S., Gevaert P., Pridgeon C., Rankin S.M., et al. Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J Immunol 170 (2003) 5359-5366
23. Murata Y., Takaki S., Migita M., Kikuchi Y., Tominaga A., and Takatsu K. Molecular cloning and expression of the human interleukin 5 receptor. J Exp Med 175 (1992) 341-351
24. Tavernier J., Tuypens T., Plaetinck G., Verhee A., Fiers W., and Devos R. Molecular basis of the membrane-anchored and two soluble isoforms of the human interleukin 5 receptor alpha subunit. Proc Natl Acad Sci U S A 89 (1992) 7041-7045
25. Tavernier J., Tuypens T., Verhee A., Plaetinck G., Devos R., Van der Heyden J., et al. Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist. Proc Natl Acad Sci U S A 92 (1995) 5194-5198
26. Tuypens T., Plaetinck G., Baker E., Sutherland G., Brusselle G., Fiers W., et al. Organization and chromosomal localization of the human interleukin 5 receptor alpha-chain gene. Eur Cytokine Netw 3 (1992) 451-459